WFRF:(Mattsson Tomas)
Search: WFRF:(Mattsson Tomas) > Serum levels of LIG...
- 37 of 72
- Previous record
- Next record
- To hitlist
Serum levels of LIGHT in MS
-
- Malmeström, Clas, 1965 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
- Gillett, Alan (author)
-
- Jernås, Margareta, 1961 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
- show more...
- show less...
- (creator_code:org_t)
- 2012-10-04
- 2013
- English.
- In: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1477-0970 .- 1352-4585. ; 19:7, s. 871-876
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- BACKGROUND: Recently, a polymorphism in the LIGHT gene was shown to increase the risk of multiple sclerosis (MS) in a genome-wide association study (GWAS). OBJECTIVE: Our aim was to investigate if serum levels of LIGHT were affected by this polymorphism and by the disease itself. METHODS: Serum levels of LIGHT were investigated in four cohorts; 1) MS (n = 159) and controls (n = 160) in relation to rs1077667 genotype; 2) MS at relapse (n = 30) vs. healthy controls (n = 26); 3) MS (n = 27) vs. other neurological disease (OND, n = 33); and 4) MS patients before and after one year of treatment with natalizumab (n = 30). RESULTS: Carriers of the GG genotype had the lowest serum levels of LIGHT (p=0.02). Serum levels of LIGHT were increased in MS at relapse in two separate cohorts: vs. healthy controls (p=0.00005) and vs. remission (p=0.00006), other neurological disease (OND) (p=0.002) and OND with signs of inflammation (iOND; p=0.00005). Furthermore, serum levels of LIGHT were decreased by natalizumab treatment (p=0.001). CONCLUSION: Soluble LIGHT is an inhibitor of T-cell activation and GG carriers of rs1077667, with the highest risk for MS, had the lowest serum levels. The increased levels of LIGHT at times of increased MS activity suggest that soluble LIGHT is protective and may act to limit inflammation.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Keyword
- Multiple sclerosis; relapsing-remitting; LIGHT; natalizumab; serum; natalizumab
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Multiple sclerosis (Houndmills, Basingstoke, England) (Search for host publication in LIBRIS)
To the university's database
- 37 of 72
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Malmeström, Clas ...
- Gillett, Alan
- Jernås, Margaret ...
- Khademi, Mohsen
- Axelsson, Markus ...
- Kockum, Ingrid
- show more...
- Mattsson, Niklas ...
- Zetterberg, Henr ...
- Blennow, Kaj, 19 ...
- Alfredsson, Lars
- Wadenvik, Hans, ...
- Lycke, Jan, 1956
- Olsson, Tomas
- Olsson, Bob, 196 ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- Articles in the publication
- Multiple scleros ...
- By the university
- University of Gothenburg
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
